Humalog
Humalog is a brand name for insulin lispro, a rapid-acting insulin analog used to improve glycemic control in people with diabetes mellitus. Developed by Eli Lilly, it was approved for medical use in the United States in 1996. Lispro differs from human insulin by swapping two amino acids at positions B28 and B29, which accelerates absorption after subcutaneous injection.
Use and administration: Humalog is delivered by subcutaneous injection or via an insulin pump to provide mealtime
Pharmacokinetics: Onset of action is about 15 minutes, with peak activity around 1–2 hours, and a duration
Formulations: Humalog is available as a rapid-acting U-100 solution for vials and prefilled pens, and a concentrated
Safety and storage: Dosing is individualized; common adverse effects include hypoglycemia, allergic reactions, lipodystrophy at injection